Multivitamin use linked to surprising shift in biological age

X Facebook WhatsApp

A new analysis of a large clinical trial finds that a daily multivitamin produced a small but measurable slowing of biological aging in older adults — not a dramatic reversal but a detectable change on DNA-based aging tests. That matters because it’s one of the first randomized, well-controlled signals that an inexpensive, over-the-counter supplement can nudge markers tied to aging.

The study draws on the long-running COSMOS trial and focuses on blood-based measures known as epigenetic clocks, which estimate biological age from DNA methylation patterns. Researchers report that participants taking a daily multivitamin showed a modest slowdown on two clock models compared with placebo over roughly two years.

How the trial worked

The original COSMOS trial enrolled more than 21,000 U.S. adults between 2014 and 2020. Participants, whose average age was about 72, were randomly assigned to receive a daily multivitamin, a cocoa extract supplement, both interventions, or a placebo. For the new analysis published in Nature Medicine, scientists analyzed blood samples from roughly 1,000 volunteers to track changes in biological aging.

Two DNA-based measures — PCPhenoAge and PCGrimAge — were used to estimate how quickly participants’ biology was aging. Compared with placebo, the multivitamin group experienced a slowed progression on these clocks equivalent to about 1.4 to 2.6 months over the study period.

Key takeaways

Study type: Randomized, placebo-controlled clinical trial (COSMOS) with a nested blood-sample analysis.

Population: Older adults, average age ~72; analysis used ~1,000 participants who provided blood samples.

Result size: Multivitamin use associated with a slowing on epigenetic clocks of roughly 1.4–2.6 months over ~2 years versus placebo.

Stronger effect: Those showing faster biological aging at baseline had the largest gains.

Limitations: Short follow-up for aging outcomes, focus on older adults, and uncertainty about how small clock changes map to real-world health or lifespan.

Researchers emphasize the modesty of the effect. The change is measurable on molecular clocks but far from a dramatic extension of life expectancy. Still, because the COSMOS trial is large and randomized, the finding is harder to dismiss than many observational or small supplement studies.

Why scientists remain cautious

Epigenetic clocks are promising tools but still an indirect measure: they estimate biological age based on DNA marks, and the field is working to tie small shifts in those marks to meaningful clinical outcomes such as reduced disease or longer survival. The new work does not show that multivitamins prevent major illnesses or extend lifespan directly.

Another key uncertainty is generalizability. The trial focused on older adults, so it’s unclear whether younger people would see a similar effect or whether different formulations or dosages would change the outcome.

What this means for readers

The main takeaway is incremental. A daily multivitamin produced a detectable change on molecular aging tests in older adults — a small nudge rather than a breakthrough. For researchers, the paper points to an accessible intervention worth further study; for the public, it provides cautious evidence that a cheap, widely available product may slightly influence biological markers tied to aging.

Next research steps include longer follow-up to check clinical outcomes, repeating analyses in younger populations, and clarifying which nutrients drive the signal. Until then, the result adds nuance to the debate over multivitamins: not useless, not miraculous — but potentially relevant in small, measurable ways.